Skip to content
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Gynecology

Hormone Replacement Therapy: Restoring Your Balance

At a Glance

For FXPOI, hormone replacement therapy replaces missing estrogen, helps relieve symptoms and protect bone health, and usually continues until about age 50 or 51. If you have a uterus, progestogen protects its lining, and HRT does not prevent pregnancy.

When you are diagnosed with Fragile X-Associated Primary Ovarian Insufficiency (FXPOI), your body stops producing the levels of estrogen and progesterone it normally would. Hormone Replacement Therapy (HRT) is the standard of care to “replace” these missing hormones [1][2].

Unlike treatment for women who go through menopause at the typical age (around 51), HRT for POI is not just about treating symptoms like hot flashes. It is about protecting your long-term health, helping to reduce the consequences of early hypoestrogenism, specifically bone loss, by restoring hormone levels to what they would naturally be in your 20s or 30s [2][3]. However, while it is beneficial, it does not completely restore normal ovarian function or provide a proven absolute guarantee of cardiovascular protection.

Physiological Dosing: Why More is Often Needed

Because you are replacing hormones that your body should be making at this stage of life, the doses used for FXPOI are typically higher than those used for older women in menopause [4][3]. This is often called physiological replacement—aiming to match the hormone environment of a premenopausal woman.

While the exact regimen depends on your symptoms, bone response, bleeding, and comorbidities, common clinician-guided examples for effective replacement include:

  • Transdermal Estrogen: 100 micrograms (0.1 mg) per day via a patch or gel [5].
  • Oral Estrogen: 2 mg per day of 17β-estradiol [5].
    These are examples, not universal required doses; there is no single universally required serum estradiol target.

Methods of Treatment

There are two main hormones involved in HRT: estrogen (to replace what the ovaries make) and progestogen (to protect the lining of the uterus).

1. Estrogen Delivery

  • Transdermal (Patches or Gels): This is often the preferred route for FXPOI [6][7]. When estrogen is absorbed through the skin, it goes directly into the bloodstream, bypassing the liver. This method is associated with a lower risk of blood clots (venous thromboembolism or VTE) and has less impact on triglyceride levels compared to pills [8][9].
  • Oral (Pills): Some women prefer the convenience of a daily pill. While effective, oral estrogen can slightly increase the risk of blood clots in some populations [8].

(Note: Low-dose vaginal estrogen may be considered for genitourinary symptoms, but it does not replace systemic estrogen for bone protection.)

2. Progestogen (If you have a uterus)

If you still have your uterus, taking estrogen alone can cause the lining of the uterus to thicken, which increases the risk of uterine cancer. To prevent this, an adequate, evidence-based dose and schedule of a progestogen (a synthetic or natural form of progesterone) must be added for endometrial protection [10][11].

  • Cyclical Regimen: You take progesterone for about 12–14 days each month, which usually results in a predictable monthly bleed [12][13]. Irregular bleeding is common early in treatment.
  • Continuous Regimen: You take a lower dose of progesterone every day, which often eventually stops periods altogether [7].
  • LNG-IUD: A hormonal IUD can sometimes provide both contraception and local endometrial protection.

Duration of Treatment

The general medical consensus is that you should continue HRT until at least the average age of natural menopause, which is approximately 50 to 51 years old [14][15]. At that point, you and your doctor can discuss whether to taper off the hormones or continue them based on your symptoms and health goals.

Safety and Contraindications

For most women with FXPOI, the benefits of HRT help mitigate symptoms and health risks. However, management must be individualized, and specialist review is needed for certain conditions:

  • Estrogen-Sensitive Cancers: Active or prior breast or endometrial cancer requires specialized consideration [16][17].
  • Blood Clots (VTE) or Arterial Disease: If you have a history of blood clots, thrombophilia, or stroke, your management must be individualized. Transdermal estrogen is not automatically safe for someone with a prior clot; this requires specialist review [8][18].
  • Unexplained Vaginal Bleeding: Any unusual bleeding must be investigated before starting or adjusting hormones [16].
  • Active Liver Disease.

A Note on Contraception

It is a common misconception that HRT acts as birth control. While FXPOI means ovulation is rare and unpredictable, spontaneous pregnancies do happen [15]. If you do not wish to become pregnant, you may need to use a separate form of contraception. Combined Hormonal Contraceptives (like the pill or ring) are an alternative option for some patients, but they are not automatically interchangeable with POI HRT and should not be combined with systemic HRT without clinician direction [2][19].

Common questions in this guide

Why is HRT recommended when I have FXPOI?
HRT replaces hormones that the ovaries would normally produce before natural menopause. It helps relieve low-estrogen symptoms and reduce the health effects of early hormone loss, especially bone loss, but it does not restore normal ovarian function or guarantee cardiovascular protection.
What estrogen dose is usually used for FXPOI?
Clinicians often use doses intended to match premenopausal hormone levels, such as a 100-microgram-per-day patch or gel or 2 mg of oral estradiol daily. The right dose depends on symptoms, bone response, bleeding, and other health conditions, and there is no single required blood estradiol target.
Is an estrogen patch safer than an estrogen pill?
Estrogen through a patch or gel bypasses the liver and is often preferred because it is associated with a lower risk of blood clots and less effect on triglycerides than oral estrogen in some populations. A patch is not automatically safe if you have had a clot or stroke, so the route should be chosen with a clinician.
Why do I need progestogen with estrogen if I still have my uterus?
If you have a uterus, estrogen alone can thicken its lining and increase the risk of uterine cancer. Progestogen protects the lining; it may be taken for about 12–14 days each month or in a lower daily dose, and a hormonal IUD may sometimes provide local protection.
How long should I take HRT for FXPOI?
The usual recommendation is to continue HRT until about age 50 or 51, the average age of natural menopause. Then you and your clinician can decide whether to taper, stop, or continue based on symptoms, health risks, and goals.
Can HRT prevent pregnancy?
No. HRT is not birth control, and ovulation can occasionally happen with FXPOI, so a separate contraceptive method may be needed if you want to avoid pregnancy. Combined hormonal contraception may be an alternative for some people, but it should not be combined with systemic HRT without clinician guidance.
What health conditions need special review before starting HRT?
Specialist review is important with a current or previous estrogen-sensitive cancer, a history of blood clots, thrombophilia, stroke, unexplained vaginal bleeding, or active liver disease. These conditions do not have one universal plan, so the benefits and risks of HRT should be assessed individually.

Get notified when new evidence is published on Fragile X-associated primary ovarian insufficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (19)
  1. 1

    Management of menopause.

    Magraith K, Jang C

    Australian prescriber 2023; (46(3)):48-53 doi:10.18773/austprescr.2023.014.

    PMID: 38053812
  2. 2

    HRT for women with premature ovarian insufficiency: a comprehensive review.

    Webber L, Anderson RA, Davies M, et al.

    Human reproduction open 2017; (2017(2)):hox007 doi:10.1093/hropen/hox007.

    PMID: 30895225
  3. 3

    Hormone therapy regimens for managing the menopause and premature ovarian insufficiency.

    Armeni E, Paschou SA, Goulis DG, Lambrinoudaki I

    Best practice & research. Clinical endocrinology & metabolism 2021; (35(6)):101561 doi:10.1016/j.beem.2021.101561.

    PMID: 34274232
  4. 4

    Long-term health consequences of premature or early menopause and considerations for management.

    Faubion SS, Kuhle CL, Shuster LT, Rocca WA

    Climacteric : the journal of the International Menopause Society 2015; (18(4)):483-91 doi:10.3109/13697137.2015.1020484.

    PMID: 25845383
  5. 5

    Improving Treatment of Radiation-Induced Premature Ovarian Insufficiency After Cervical Cancer: A Practice Quality Improvement Initiative.

    Smith EE, Heintz JR, Chesnokova A, Taunk NK

    International journal of radiation oncology, biology, physics 2026; (126(1)):48-54 doi:10.1016/j.ijrobp.2026.02.211.

    PMID: 41698471
  6. 6

    Expert opinion by the Italian Society of Gynecology of the Third Age (SIGiTE) and the Italian Society of Menopause (SIM) on diagnosis and treatment of premature ovarian insufficiency.

    Capozzi A, Ambroggio S, Cagnacci A, et al.

    Minerva endocrinology 2026; (51(1)):88-95 doi:10.23736/S2724-6507.25.04422-7.

    PMID: 41212137
  7. 7

    Premature ovarian insufficiency: Updated concepts in diagnosis and hormonal treatment strategies.

    Pravatta-Rezende G, Benetti-Pinto CL, Yela DA, et al.

    Clinics (Sao Paulo, Brazil) 2025; (80()):100745 doi:10.1016/j.clinsp.2025.100745.

    PMID: 40840112
  8. 8

    Menopause-associated risk of cardiovascular disease.

    Anagnostis P, Lambrinoudaki I, Stevenson JC, Goulis DG

    Endocrine connections 2022; (11(4)).

    PMID: 35258483
  9. 9

    Menopausal Hormone Therapy and Cardiovascular Risk: Where are we Now?

    Anagnostis P, Paschou SA, Katsiki N, et al.

    Current vascular pharmacology 2019; (17(6)):564-572 doi:10.2174/1570161116666180709095348.

    PMID: 29984659
  10. 10

    Hormone replacement therapy in gynecologic cancer survivors: bridging the gap between evidence and clinical practice.

    Gil-Ibáñez B, Luzarraga Aznar A, Barretina-Ginesta MP, et al.

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2026; 104881 doi:10.1016/j.ijgc.2026.104881.

    PMID: 42660774
  11. 11

    Hormone therapy in women with premature ovarian insufficiency: a systematic review and meta-analysis.

    Gonçalves CR, Vasconcellos AS, Rodrigues TR, et al.

    Reproductive biomedicine online 2022; (44(6)):1143-1157 doi:10.1016/j.rbmo.2022.02.006.

    PMID: 35461762
  12. 12

    Isolated β-Human Chorionic Gonadotropin Elevation-From Pregnancy to Fragile X-associated Premature Ovarian Insufficiency.

    Sharma PP

    AACE endocrinology and diabetes 2026; (13(2)):308-312 doi:10.1016/j.aed.2025.11.008.

    PMID: 41938280
  13. 13

    Hormone therapy for uterine and endometrial development in women with premature ovarian insufficiency.

    Craciunas L, Zdoukopoulos N, Vinayagam S, Mohiyiddeen L

    The Cochrane database of systematic reviews 2022; (10()):CD008209 doi:10.1002/14651858.CD008209.pub2.

    PMID: 36200708
  14. 14

    Primary ovarian insufficiency: a toolkit for the busy clinician.

    Kapoor E

    Menopause (New York, N.Y.) 2024; (31(1)):65-67 doi:10.1097/GME.0000000000002275.

    PMID: 38086010
  15. 15

    Committee Opinion No. 698: Hormone Therapy in Primary Ovarian Insufficiency.

    Obstetrics and gynecology 2017; (129(5)):e134-e141 doi:10.1097/AOG.0000000000002044.

    PMID: 28426619
  16. 16

    Premature ovarian insufficiency: When ovaries retire early.

    Sugianto SRS, Webber L, Safdar Husain F, et al.

    Annals of the Academy of Medicine, Singapore 2025; (54(3)):178-191 doi:10.47102/annals-acadmedsg.2024227.

    PMID: 40178424
  17. 17

    Hormonal management of menopausal symptoms in women with a history of gynecologic malignancy.

    Harris BS, Bishop KC, Kuller JA, et al.

    Menopause (New York, N.Y.) 2020; (27(2)):243-248 doi:10.1097/GME.0000000000001447.

    PMID: 31738735
  18. 18

    [Menopause and risk of thromboembolic events. Postmenopausal women management: CNGOF and GEMVi clinical practice guidelines].

    Hugon-Rodin J, Perol S, Plu-Bureau G

    Gynecologie, obstetrique, fertilite & senologie 2021; (49(5)):455-461 doi:10.1016/j.gofs.2021.03.018.

    PMID: 33757918
  19. 19

    Position statement on the diagnosis and management of premature/primary ovarian insufficiency (except Turner Syndrome).

    Christin-Maitre S, Givony M, Albarel F, et al.

    Annales d'endocrinologie 2021; (82(6)):555-571 doi:10.1016/j.ando.2021.09.001.

    PMID: 34508691

This page provides educational information about hormone replacement therapy for FXPOI and is not medical advice. Your clinician should tailor the estrogen dose, progestogen plan, and contraception to your health history.